EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

HER2-Altered Non-Small Cell Lung Cancer: A Journey from Current Approaches to Emerging Strategies

Giorgia Ferrari iD, Benedetta Del Rio iD, Silvia Novello, Francesco Passiglia

Cancers · 26.05.2024 · 16 (11) · 2018

DOI: 10.3390/cancers16112018 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 26.05.2024. Verfasst von Giorgia Ferrari und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, University of Turin, San Luigi Hospital, 10124 Orbassano, Italy. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 70 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

For patients diagnosed with advanced HER2-altered non-small cell lung cancer (NSCLC), the current standard of care is represented by a platinum-pemetrexed-based chemotherapy, eventually in combination with immunotherapy. Different pan-HER tyrosine kinase inhibitors have been evaluated in limited phase II trials, yielding generally unsatisfactory outcomes, although certain genotypes demonstrated some clinical benefit. Conversely, antibody-drug conjugates (ADCs) targeting HER2, particularly trastuzumab-deruxtecan, have shown promising results against HER2-mutant disease, including a great intracranial activity in patients with brain metastasis. Based on the results obtained from DESTINY-Lung01 and DESTINY-Lung02 trials, trastuzumab deruxtecan received regulatory approval as the first targeted therapy for pre-treated, HER2-mutant, advanced NSCLC patients. More recently, the Food and Drug Administration (FDA) granted the accelerated approval of trastuzumab deruxtecan for advanced, pre-treated HER2-positive solid tumours with no other treatment options. In this scenario, emerging evidence is increasingly pointing towards the exploration of combination regimens with synergistic effects in the advanced disease. In this review, we provide a detailed summary of current approaches and emerging strategies in the management of HER2-altered NSCLC, also focusing on unmet needs, including the treatment of patients with brain metastases.

Schlagwörter

Stichwörter der Autor:innen

HER2antibody-drug conjugatesnon-small cell lung cancertargeted therapy

Autor:innen und Institutionen

  • Department of Oncology, University of Turin, San Luigi Hospital, 10124 Orbassano, Italy.

ORCID-Profile: Giorgia Ferrari, Benedetta Del Rio

Zitieren

APA

Ferrari, G., Del Rio, B., Novello, S., & Passiglia, F. (2024). HER2-Altered Non-Small Cell Lung Cancer: A Journey from Current Approaches to Emerging Strategies. Cancers, 16(11), 2018. https://doi.org/10.3390/cancers16112018

Vancouver

Ferrari G, Del Rio B, Novello S, Passiglia F. HER2-Altered Non-Small Cell Lung Cancer: A Journey from Current Approaches to Emerging Strategies. Cancers. 2024;16(11):2018. doi:10.3390/cancers16112018

BibTeX
@article{Ferrari2024,
  author = {Ferrari, Giorgia and Del Rio, Benedetta and Novello, Silvia and Passiglia, Francesco},
  title = {HER2-Altered Non-Small Cell Lung Cancer: A Journey from Current Approaches to Emerging Strategies},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {11},
  pages = {2018},
  doi = {10.3390/cancers16112018}
}
Kostenlos starten →